323 related articles for article (PubMed ID: 11756773)
1. Immunoprofile of MITF, tyrosinase, melan-A, and MAGE-1 in HMB45-negative melanomas.
Xu X; Chu AY; Pasha TL; Elder DE; Zhang PJ
Am J Surg Pathol; 2002 Jan; 26(1):82-7. PubMed ID: 11756773
[TBL] [Abstract][Full Text] [Related]
2. Microphthalmia transcription factor in the immunohistochemical diagnosis of metastatic melanoma: comparison with four other melanoma markers.
Miettinen M; Fernandez M; Franssila K; Gatalica Z; Lasota J; Sarlomo-Rikala M
Am J Surg Pathol; 2001 Feb; 25(2):205-11. PubMed ID: 11176069
[TBL] [Abstract][Full Text] [Related]
3. Microphthalmia transcription factor and melanoma cell adhesion molecule expression distinguish desmoplastic/spindle cell melanoma from morphologic mimics.
Koch MB; Shih IM; Weiss SW; Folpe AL
Am J Surg Pathol; 2001 Jan; 25(1):58-64. PubMed ID: 11145252
[TBL] [Abstract][Full Text] [Related]
4. Comparison of immunohistochemical labelling of melanocyte differentiation antibodies melan-A, tyrosinase and HMB 45 with NKIC3 and S100 protein in the evaluation of benign naevi and malignant melanoma.
Orchard GE
Histochem J; 2000 Aug; 32(8):475-81. PubMed ID: 11095072
[TBL] [Abstract][Full Text] [Related]
5. Tyrosinase expression in malignant melanoma, desmoplastic melanoma, and peripheral nerve tumors.
Boyle JL; Haupt HM; Stern JB; Multhaupt HA
Arch Pathol Lab Med; 2002 Jul; 126(7):816-22. PubMed ID: 12088451
[TBL] [Abstract][Full Text] [Related]
6. The usefulness of tyrosinase in the immunohistochemical assessment of melanocytic lesions: a comparison of the novel T311 antibody (anti-tyrosinase) with S-100, HMB45, and A103 (anti-melan-A).
Clarkson KS; Sturdgess IC; Molyneux AJ
J Clin Pathol; 2001 Mar; 54(3):196-200. PubMed ID: 11253130
[TBL] [Abstract][Full Text] [Related]
7. Microphthalmia transcription factor: not a sensitive or specific marker for the diagnosis of desmoplastic melanoma and spindle cell (non-desmoplastic) melanoma.
Granter SR; Weilbaecher KN; Quigley C; Fletcher CD; Fisher DE
Am J Dermatopathol; 2001 Jun; 23(3):185-9. PubMed ID: 11391097
[TBL] [Abstract][Full Text] [Related]
8. Immunophenotypic differences between uveal and cutaneous melanomas.
Iwamoto S; Burrows RC; Kalina RE; George D; Boehm M; Bothwell MA; Schmidt R
Arch Ophthalmol; 2002 Apr; 120(4):466-70. PubMed ID: 11934320
[TBL] [Abstract][Full Text] [Related]
9. Expression of the B-cell proliferation marker MUM1 by melanocytic lesions and comparison with S100, gp100 (HMB45), and MelanA.
Sundram U; Harvell JD; Rouse RV; Natkunam Y
Mod Pathol; 2003 Aug; 16(8):802-10. PubMed ID: 12920225
[TBL] [Abstract][Full Text] [Related]
10. Expression of melanocytic differentiation markers in malignant melanomas of the oral and sinonasal mucosa.
Prasad ML; Jungbluth AA; Iversen K; Huvos AG; Busam KJ
Am J Surg Pathol; 2001 Jun; 25(6):782-7. PubMed ID: 11395556
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of eight melanocytic and neural crest-associated markers in a well-characterised series of 124 malignant peripheral nerve sheath tumours (MPNST): useful to distinguish MPNST from melanoma?
Gaspard M; Lamant L; Tournier E; Valentin T; Rochaix P; Terrier P; Ranchere-Vince D; Coindre JM; Filleron T; Le Guellec S
Histopathology; 2018 Dec; 73(6):969-982. PubMed ID: 30137667
[TBL] [Abstract][Full Text] [Related]
12. A103: An anti-melan-a monoclonal antibody for the detection of malignant melanoma in paraffin-embedded tissues.
Jungbluth AA; Busam KJ; Gerald WL; Stockert E; Coplan KA; Iversen K; MacGregor DP; Old LJ; Chen YT
Am J Surg Pathol; 1998 May; 22(5):595-602. PubMed ID: 9591730
[TBL] [Abstract][Full Text] [Related]
13. Comparison of five antibodies as markers in the diagnosis of melanoma in cytologic preparations.
Sheffield MV; Yee H; Dorvault CC; Weilbaecher KN; Eltoum IA; Siegal GP; Fisher DE; Chhieng DC
Am J Clin Pathol; 2002 Dec; 118(6):930-6. PubMed ID: 12472287
[TBL] [Abstract][Full Text] [Related]
14. Analysis of microphthalmia transcription factor expression in normal tissues and tumors, and comparison of its expression with S-100 protein, gp100, and tyrosinase in desmoplastic malignant melanoma.
Busam KJ; Iversen K; Coplan KC; Jungbluth AA
Am J Surg Pathol; 2001 Feb; 25(2):197-204. PubMed ID: 11176068
[TBL] [Abstract][Full Text] [Related]
15. Comparison of immunohistochemical staining of the novel antibody melan-A with S100 protein and HMB-45 in malignant melanoma and melanoma variants.
Blessing K; Sanders DS; Grant JJ
Histopathology; 1998 Feb; 32(2):139-46. PubMed ID: 9543670
[TBL] [Abstract][Full Text] [Related]
16. Melan-A/Mart-1 expression in various melanocytic lesions and in non-melanocytic soft tissue tumours.
Orosz Z
Histopathology; 1999 Jun; 34(6):517-25. PubMed ID: 10383696
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical study of microphthalmia transcription factor and tyrosinase in angiomyolipoma of the kidney, renal cell carcinoma, and renal and retroperitoneal sarcomas: comparative evaluation with traditional diagnostic markers.
Zavala-Pompa A; Folpe AL; Jimenez RE; Lim SD; Cohen C; Eble JN; Amin MB
Am J Surg Pathol; 2001 Jan; 25(1):65-70. PubMed ID: 11145253
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical diagnosis of malignant melanoma of the conjunctiva and uvea: comparison of the novel antibody against melan-A with S100 protein and HMB-45.
Heegaard S; Jensen OA; Prause JU
Melanoma Res; 2000 Aug; 10(4):350-4. PubMed ID: 10985669
[TBL] [Abstract][Full Text] [Related]
19. Is MAGE-1 expression in metastatic malignant melanomas really helpful?
Gajjar NA; Cochran AJ; Binder SW
Am J Surg Pathol; 2004 Jul; 28(7):883-8. PubMed ID: 15223957
[TBL] [Abstract][Full Text] [Related]
20. Microphthalmia transcription factor expression in cutaneous benign, malignant melanocytic, and nonmelanocytic tumors.
King R; Googe PB; Weilbaecher KN; Mihm MC; Fisher DE
Am J Surg Pathol; 2001 Jan; 25(1):51-7. PubMed ID: 11145251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]